PCR Rio Valves 2025: Advancing Minimally Invasive Therapies for Tricuspid Valve Disease
The inaugural PCR Rio Valves 2025 took place on September 11–12, 2025, in Rio de Janeiro, Brazil, representing the first international meeting in the country dedicated to valvular heart disease and structural heart interventions. P&F Products & Features was proud to participate in this two-day event, convening specialists in interventional cardiology, cardiac surgery, and cardiovascular imaging to exchange knowledge, review contemporary evidence, and discuss future strategies in valve therapy.
The scientific program combined live case demonstrations, advanced imaging workshops, and multidisciplinary Heart Team sessions, with the objective of fostering innovation and strengthening international collaboration in cardiovascular care.
P&F sponsored session “Minimalist approach to tricuspid valve therapy,” highlighted the role of the TricValve® device in the management of tricuspid regurgitation. Clinical case presentations illustrated the feasibility of a minimally invasive, non-contrast, transthoracic echocardiography-guided approach for TricValve® implantation. The data emphasized procedural safety while demonstrating effective hemodynamic improvements. In addition, clinical outcomes were presented showing enhancements in patient quality of life, reductions in hospitalization rates, and decreases in right ventricular pressures following device implantation.
The session underscored the evolving role of percutaneous tricuspid interventions within the broader field of structural heart disease, reflecting the ongoing shift toward less invasive, patient-tailored treatment strategies.
As the first edition of PCR Rio Valves, the meeting served as a platform to integrate global expertise and highlight innovation in structural interventions. Future iterations are expected to continue advancing the evidence base and expanding access to novel valve therapies worldwide.
